Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics Inc.

In a report released today, from Roth MKM reiterated a Buy rating on Fulcrum Therapeutics, with a price target of $15.00. In addition to Roth MKM, ...

Fulcrum Therapeutics (FULC) Receives a Buy from Roth MKM

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), Fulcrum Therapeut...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Fulcrum Therapeutics (FULC) and Arcellx Inc (ACLX)

In a report released on December 6, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Fulcrum Therapeutics, with a price target of $...

Cantor Fitzgerald Remains a Buy on Fulcrum Therapeutics (FULC)

In a report released today, James Condulis from Stifel Nicolaus maintained a Buy rating on Fulcrum Therapeutics, with a price target of $20.00. Con...

Stifel Nicolaus Remains a Buy on Fulcrum Therapeutics (FULC)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Fulcrum Therapeutics today and set a price target of $15.00. Biegler covers the Heal...

Fulcrum Therapeutics (FULC) Receives a Buy from Oppenheimer

Fulcrum Therapeutics ( ($FULC) ) just unveiled an announcement. On December 6, 2025, Fulcrum Therapeutics announced positive initial results from t...

Fulcrum Therapeutics Reports Positive Phase 1b Trial Results

Truist Financial analyst maintained a Buy rating on Fulcrum Therapeutics yesterday. The company’s shares closed yesterday at $9.06. In addition to ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FULC	$13.00	+1.56%	1.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FULC	$13.00	+1.6%	1.63M
3
4
5
6

FULC

FULC

Dividend Overview

Get Fulcrum Therapeutics Inc. Data in Excel

Get Fulcrum Therapeutics Inc. Data in Excel